INTRODUCTION
============

Neuropathy is the one of the most common and debilitating long term complication of diabetes affecting up to 50% of patients \[[@B1]-[@B4]\]. Diabetic peripheral neuropathy (DPN) is defined in the clinical practice as the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes \[[@B5]\]. Prevalence of DPN may vary from 30% to 40% in type 1 and 2 diabetic patients \[[@B6]\]. Signs and symptoms of DPN vary depending on fiber type involved, with large fiber disease impairing proprioception and light touch. Small fiber disease impairs pain and temperature perception, leading to paresthesias, dysesthesias, and/or neuropathic pain. DPN may cause muscle weakness and diminished or absent deep-tendon reflexes, especially the Achilles tendon reflex. More advanced disease may lead to foot deformities like hammer toes, collapse of the mid foot, ulceration or neuroarthropathy (Charcot joints) of the foot may occur \[[@B7]\]. Symptoms may go unnoticed for a long period. Spread of the untreated infection to bone may lead to amputation. The immense physical, psychological, and economic cost of diabetic neuropathy underscore the need for causally targeted therapies \[[@B7]\].

Several pathogenetic mechanisms have been proposed for diabetic neuropathy (DN) like polyol pathway, glycation, myoinositol, oxidative stress, nerve hypoxia, and protein kinase C (PKC), etc. \[[@B8]\]. The classes of drugs used to treat DPN based on these mechanisms are aldose reductase inhibitor (ARI) \[[@B9]\], vasodilators, PKC-β inhibitors \[[@B10]\], and others \[[@B8]\]. The prevention of the onset or modifying the natural history of DPN by targeting known pathogenetic mechanisms is mostly in experimental stages and not therefore available for clinical usage at present.

ARIs like sorbinil, tolrestat, ponalrestat, zopolrestat, zenarestat, epalrestat, ranirestat, and fidarestat have been found to be acting on the progression of DN \[[@B9]\]. Recent Cochrane review of 32 clinical trials (*n*=4,970) revealed no statistically significant overall benefit of ARI in DN \[[@B11]\]. Only one ARI molecule epalrestat is approved for clinical use in Japan \[[@B12]\].

Another important class of drug to be used in DPN is PKC-β inhibitors. The putative mechanism is that intracellular hyperglycaemia cause increase in diacylglycerol (DAG) levels, activating PKC formation, leading to multiple pathogenetic consequences including altered expression of endothelial nitric oxide synthetase and angiogenic protein vascular endothelial growth factor (VEGF). This leads to the development of diabetic complications like neuropathy. PKC pathway activation alters vasoconstriction and capillary permeability, and can cause hypoxia, angiogenesis, basement membrane thickening, and endothelial proliferation. These changes in neurovascular blood flKC are the likely source of PKC\'s role in neuropathy. Thus PKC inhibitor has been thought to be a potential disease modifying drug in DPN \[[@B10]\].

Ruboxistaurin (RBX) is an orally active PKC-β inhibitor. It binds to the active site of PKC-β, thus interfering with adenosine triphosphate binding and inhibiting phosphorylation of substrates. RBX gets metabolized by CYP3A4 to its main equipotent metabolite, N-desmethyl RBX \[[@B13]\]. The half-life of RBX and its metabolite combined is 24 hours, thereby allowing once daily dosing. Studies showed that the primary excretion route in humans for these substances was faecal with renal elimination playing a minor role. Thus, renal impairment does not preclude its use \[[@B14]\]. RBX can also be used for other diabetic complications like retinopathy, nephropathy, and heart failure.

Treatments that could prevent, improve, or even slow the progression of DPN would result in decreased morbidity, cost and improved quality of life (QoL) of patients with diabetes mellitus. RBX is therefore considered a valuable target molecule for therapeutic intervention. The present systematic review assesses the efficacy and safety data available of RBX on the progression of symptoms, signs or functional disability in DPN.

METHODS
=======

Search strategy
---------------

We searched for randomized controlled clinical trials on RBX in databases PubMed, ProQuest, EBSCO, EMBASE, and Cochrane Central up to August 2012. Keywords included: \'Ruboxistaurin, PKC inhibitor, LY 333531 AND Neuropathy, DPN, Diabetic polyneuropathy\' where we kept limits namely \'Human\' and \'Clinical trials.\' We have also searched on American Diabetes Association website for conference proceedings. We also searched electronic registers of ongoing trials such as the Current Controlled Trials register (<http://www.controlled-trials.com/>). Bibliographies of the identified randomized trials were also searched. We also tried to contact the authors to identify additional published or unpublished data. We also searched (<http://www.clinicaltrials.gov/>) and found two registered clinical trials with clinical trial registry number NCT00044408 and NCT00044395; full published studies regarding these trials could not be retrieved.

We included randomized controlled trials (RCTs), regardless of publication status, language, or period of patient inclusion. Intervention used was PKC inhibitor, i.e., RBX and compared with placebo and/or active comparator. As rate of progression of DPN is slow, any short-duration intervention will not produce a detectable effect. Therefore, only trials with treatment lasting at least 6 months and in which criteria for diagnosis of DPN was mentioned clearly with appropriate investigations to rule out other causes of neuropathy were included.

Data collection and analysis
----------------------------

### Selection of studies

An initial inclusion/exclusion form was used to assess study inclusion in the review. The titles and abstracts of every record retrieved by the searching process were scanned. The citations were divided alphabetically by first author and each citation was assessed for inclusion independently by two review authors. Discrepancies between assessments were resolved by discussion and when necessary, in consultation with the third review author. If disagreements could not be resolved at this stage, the full article was collected and assessed. If a trial was excluded at any time after this point, a record of both the article and exclusion criteria was kept in record.

### Data extraction and management

The methodological details and data from publications or unpublished study reports were extracted independently by two reviewers. The data extraction sheet included details of: 1) publication type and date; 2) study design including use of placebo; 3) duration and dose of treatment; 4) duration of follow-up; 5) details of the inclusion and exclusion criteria of the participants, numbers of participants, number of withdrawals, and reasons for withdrawals; 6) baseline characteristics; 7) outcome measures of study; 8) results of study; and 9) adverse drug reaction.

### Assessment of risk of bias in included studies

Each included study was evaluated for the methodological quality. The characteristics assessed were; randomization methods, adequacy of allocation concealment, methods of patient and observer blinding. Each characteristic was graded as adequate, unclear, inadequate, or not done. Differences in grading by the evaluators were discussed and resolved by consensus.

### Measures of treatment effect

Improvement of sensory symptoms and nerve function were considered to be important end points \[[@B15]\]. For our review we considered assessment of change in neurological examination as a primary outcome. This can be done by measuring sensory symptoms and nerve function, for which neurological total symptom score scale (NTSS-6) \[[@B16]\] and vibration detection threshold (VDT) \[[@B17]\] are used respectively. As secondary outcome measure, change in neurological impairment score (NIS) \[[@B18]\], skin microvascular blood flow (SkBF) \[[@B19]\], QoL \[[@B20]\], safety profile and tolerability were considered.

For assessment of QoL self administered 47 item Norfolk-DN questionnaire used to measure relationship between symptomatic DN and QoL from the perspective of patient. It is composed of two parts: questions related to symptoms experienced by patient and questions related to the impact of patient\'s neuropathy on activities of daily life \[[@B18]\].

Statistical analysis
--------------------

No meta-analysis or quantitative analysis was possible due to significant heterogeneity between included studies in terms of study size, data reports, and procedure. Further, the inconsistencies in outcomes reported and the paucity of statistical data prevented quantitative meta-analysis. The review therefore consists of a qualitative assessment and narrative analysis to compare the studies. For the assessment of risk of bias in the included studies, analyses were undertaken using Review Manager 5 (RevMan; The Nordic Cochrane Centre, Copenhagen, Denmark). RevMan is the Cochrane collaboration\'s software for preparing and maintaining Cochrane reviews. Age of participant\'s at baseline of three studies has been compared using independent *t*-test using GraphPad Instat Demo 3 statistical software (GraphPad InStat Software, San Diego, CA, USA).

RESULTS
=======

Search result
-------------

Of the 296 studies retrieved from the literature databases, two conference abstracts \[[@B21],[@B22]\] and four full text articles \[[@B17],[@B19],[@B20],[@B23]\] met the inclusion criteria ([Fig. 1](#F1){ref-type="fig"}). Six of these described RCTs were of at least six months duration. A study by Tesfaye et al. \[[@B24]\] was excluded as no intervention was administered and patients were only followed to understand the natural progression of DPN.

We found three studies (one full text and two conference abstracts) \[[@B19],[@B21],[@B22]\] by same author name Carolina M. Casellini. We tried to find out whether those studies were done on same population by comparing the trial results. But study samples included in studies were found to be different and all three studies were included in our review. Casellini et al. \[[@B22]\] was performed as pilot study.

Description of studies
----------------------

### Interventions

Participants in the included studies received RBX (32 mg/day) or placebo as oral tablets for the specified duration of the study. In one study, Vinik et al. \[[@B17]\] two arms of RBX were used in which one received 32 mg/day and other received 64 mg/day dose of RBX.

### Study design

The included studies were all randomized and double blind except for two full text studies by Boyd et al. \[[@B20]\] and Casellini et al. \[[@B22]\] in which information regarding randomization and blinding was not reported ([Table 1](#T1){ref-type="table"}). Most studies lasted for 6 to 12 months and involved comparison of RBX (32 or 64 mg/day) and placebo. However, in study by Boyd et al. \[[@B20]\], topiramate (100 mg/day) was also used and compared with placebo. Diagnostic criterion for diabetes was not explicitly stated in most studies. Criteria for the diagnosis of DPN and the severity of the neuropathy, varied considerably from study to study. In most studies there was a reasonable attempt to exclude other causes of neuropathy.

### Participants

All studies recruited adult participants of 18 years and older. The six studies involved a total of 353 subjects, of which 210 received RBX, 123 received placebo, and 20 received topiramate. Both type 1 and 2 diabetic patients were recruited except in study by Boyd et al. \[[@B20]\] in which only type 2 diabetic patients were recruited.

An attempt was also made to compare the baseline characteristics of participants in the included studies ([Table 2](#T2){ref-type="table"}). Only three studies by Vinik et al. \[[@B17]\], Boyd et al. \[[@B20]\], and Brooks et al. \[[@B23]\] had reported complete data regarding participant\'s age for the statistical analysis. The participants in the studies by Vinik et al. \[[@B17]\] and Brooks et al. \[[@B23]\] were significantly younger than in the study by Boyd et al. \[[@B20]\]. The other characteristics could not be compared because of lack of documented data.

### Risk of bias

[Fig. 2](#F2){ref-type="fig"} shows the overall risk of bias involved in the studies based on sequence generation, allocation concealment, and blinding. There was unclear risk of bias in the majority of the studies based on random sequence generation and allocation concealment while high risk of bias was observed based on blinding of participants and observer.

### Effect of interventions

Most studies presented outcome data numerically in tables. Graphical presentation was also seen in some cases. The comparisons were done between RBX and placebo in all the studies. None of study compared RBX with active comparator ([Table 3](#T3){ref-type="table"}).

### Primary outcome measure

Change in NTSS-6 was assessed in all included studies. Change in VDT was the outcome measure seen in one study by Vinik et al. only \[[@B17]\].

Neurological total symptom score
--------------------------------

Change in NTSS-6 was assessed in 353 participants. Decrease in NTSS score indicates improvement. Significant decrease in NTSS score was found in RBX treated group as compared to placebo in studies three studies by Casellini et al. \[[@B19]\] (*P*\<0.037), Boyd et al. \[[@B20]\] (*P*\<0.001), Casellini et al. \[[@B22]\] (*P*\<0.04), and Casellini et al. \[[@B21]\] (*P*\<0.0006) where total of 64 participants received RBX.

No significant difference was observed in two studies conducted by Brooks et al. \[[@B23]\] and Vinik et al. \[[@B17]\]. But in Vinik et al. \[[@B17]\] study, a subgroup of patients with clinically significant symptoms (defined as NTSS-6 score \>6) at baseline (*n*=83), significant change in NTSS was observed at 12 months of follow-up in RBX 64 mg/day treated patients (*n*=71) (*P*=0.015) but not in RBX 32 mg/day group (*n*=66) as compared to placebo group. Similarly, in a subgroup of patients with clinically significant symptoms and less severe DPN (*n*=50) (defined as sural nerve action potential ≥0.5 µv and NTSS-6 rating \>6) there was a statistically significant reduction in NTSS-6 total score with RBX 64 mg/day (*P*=0.006).

Vibration detection threshold
-----------------------------

Change in VDT was assessed in only one study by Vinik et al. \[[@B17]\] study. Decrease in VDT units represents improvement. No significant improvement (*P*=not reported) was observed in VDT in both RBX treated groups (32, 64 mg/day) as compared to placebo in total of 205 patients. Decrease in VDT units was observed in a subgroup of patients with clinically significant symptoms (NTSS-6 score \>6). Significant decrease in VDT units was also observed in a subgroup of patients with clinically significant symptoms and less severe DPN (*n*=50), for RBX 32 mg/day (*P*=0.012) and 64 mg/day (*P*=0.026) as compared with placebo group.

Secondary outcome measure
-------------------------

### Skin microvascular blood flow

Change in SkBF (endothelium dependent) was assessed in four studies \[[@B19],[@B21]-[@B23]\]. Increase in SkBF represents improvement. In three studies with total of 44 RBX treated subjects, significant increase in SkBF from baseline was observed in RBX treated group as compared to placebo (*P*\<0.03, *P*\<0.013, and *P*\<0.002 respectively). In Brooks et al. \[[@B23]\] study, no significant (*P*=0.233) improvement in SkBF was found in RBX treated group (*n*=9) as compared to placebo group (*n*=9).

### Total quality of life

Change in total QoL (by Norfolk QoL-DN) was assessed in two studies recruiting a total of 80 participants. Increase in score indicates improvement. In Boyd et al. \[[@B20]\] study, significant improvement was observed in two aspects of QoL including total QoL score (*P*\<0.04) and symptom subscore (*P*\<0.004) in RBX group (*n*=20) as compared to placebo group (*n*=20). In Casellini et al. \[[@B19]\] study, significant improvement in symptom subscore was observed in RBX treated subjects as compared to placebo treated subjects (*P*=0.041). Significant improvement from baseline was observed in RBX group (*P*=0.01) but not in patients under placebo group. Similarly significant improvement of total QoL score was also observed in RBX treated group (*P*=0.04) at 6 months as compared to placebo. No significant difference for other aspects of QoL reported in either study.

### Neurological impairment score

Change in NIS was assessed in five studies in 242 participants (RBX treated group only) \[[@B17],[@B19],[@B20],[@B22],[@B23]\]. Decrease in NIS score indicates improvement. Significant decrease in NIS score was observed in RBX group as compared to placebo group in study by Casellini et al. \[[@B22]\] where data from 10 participants was used (*P*\<0.01). No significant decrease in NIS score was observed in the remaining studies in RBX group as compared to placebo group.

Safety profile
--------------

According to European Medicine Agency (EMA) report, common observed adverse effects (AEs) with the use of RBX in diabetic retinopathy are QT prolongation, creatinine phospokinase elevation. Safety was assessed in only two studies. In Casellini et al. \[[@B19]\] study 35 patients experienced treatment emergent adverse events (TEAE). No AE were considered to be study drug related. Four serious AEs were also reported in the same study in RBX group: bacterial pneumonia, myocardial ischemia, coronary artery disease with stent placement, and death resulting from acute myocardial infarction. None of serious AEs were considered to be study drug related except for myocardial ischemia, for which causal relationship could not be ruled out. In Vinik et al. \[[@B17]\] study, 161 patients experienced TEAE but none were found to be relevant. In this study 26 patients reported serious AEs (placebo-12, RBX 32 mg/day-9, RBX 64 mg/day-5). No documentation regarding AE was found in other four studies.

Tolerability
------------

Two studies documented the number and reasons of withdrawals. In Vinik et al. \[[@B17]\] study (*n*=205), 32 (15.6%) discontinued treatment. In this, AEs caused withdrawal in nine patients (RBX 32 mg/day, one; RBX 64 mg/day, four; placebo, four), lost to follow-up caused withdrawal in eight patients (RBX 32 mg/day, three; RBX 64 mg/day, one; placebo, four), withdrawal by patient decision in 11 patients (RBX 32 mg/day, three; RBX 64 mg/day, five; placebo, three) and withdrawal by physician or sponsor decision in four patients (RBX 32 mg/day, three; RBX 64 mg/day, one). Casellini et al. \[[@B19]\] study reported no patient withdrawal. While in remaining studies patient withdrawal data was not reported.

DISCUSSION
==========

DPN has been found to be a common long term microvascular complication in patients with diabetes mellitus. It is well known that hyperglycaemia leads to elevated levels of DAG, which is a potent activator of PKC. It also results in the deregulation of several cellular processes in which PKC isoenzymes are involved, including those which lead to inhibition of Na-K ATPase, increasing permeability and stimulation of proliferation in different cell types. RBX is a specific inhibitor of PKC-β enzyme which plays important role in pathogenesis of endothelial damage associated with diabetic microvascular complications \[[@B25]-[@B28]\].

RBX showed significant results in animal studies for indications such as neuropathy, retinopathy, and nephropathy associated with diabetes. Several drugs with wide array of mechanisms are under clinical investigation, such as fidarestat \[[@B8]\] and AS-3201 \[[@B29]\] (both increases polyol pathway), α-lipoic acid \[[@B8]\], phVEGF 165 gene transfer \[[@B8]\], and C-peptide \[[@B8]\].

New drug application for marketing authorization was filed by Eli Lilly for RBX (Arxxant) on February 2006 to U.S. Food and Drug Administration (USFDA) and on 30 May 2006 to the EMA for diabetic retinopathy. Approvable letter issued from USFDA, with a request for an additional clinical trial. Eli Lilly withdrew its marketing application for RBX for diabetic retinopathy due to non provision of the additional required data within the allowed timeframe \[[@B30]\]. Three clinical trials of RBX have been published since 2006. At present, no clinical trial is being registered within USFDA, EMA, and Canada. Only one clinical trial is found to be ongoing in Japan registry while no other trial is registered in other registries. There is no other molecule in PKC-β inhibitor category which could explored to be used in diabetic microvascular complications.

Improvement of sensory symptoms and nerve function are considered to be important end points. DPN is primarily a sensory disorder and measurement of sensory symptoms and nerve function must be an important outcome of therapeutic trials.

In our systematic review we observed various parameters for the assessment of DPN. NTSS-6 was assessed in all included studies out of which four observed significant decrease in NTSS-6 score in RBX group while two studies \[[@B17],[@B23]\] did not observe significant fall in NTSS-6. Also, no significant increase in VDT was observed \[[@B17]\]. This may be due to relatively short period of follow-up (12 months), since progression of DPN is slow and might require up to 3 years of follow-up to demonstrate clinically significant difference \[[@B31]\]. However, patients with less severe DPN were found to be more responsive to RBX. Measurements of SkBF showed significant improvement with RBX in three studies \[[@B19],[@B21],[@B22]\]. Significant improvement in QoL was also observed in two studies \[[@B19],[@B20]\].

Safety assessment was not done in majority of the studies except for two where none of the AE was related to RBX except for one case of myocardial ischemia in Casellini et al. \[[@B19]\] study. The safety profile was consistent with that reported in previous safety profile evaluations of RBX in healthy volunteers or patients with DM.

Some limitations of our review process must be noted. It was difficult to clarify details of study methodology of included studies. The total number of subjects in the included six studies is too small to come to firm conclusion. We could not receive any information regarding the two registered large clinical trials (*n*=200 each) of RBX in DPN. A key limitation and challenge in synthesizing and interpreting this body of evidence is the issue of heterogeneous patient populations across and within studies. There are important issues of methodological quality involving most of these studies; in a substantial number we had incomplete information about concealment of treatment allocation and methods of randomization and blinding. Moreover, most of the studies included in this systematic review lacked proper reporting the statistical values which precluded the quantitative pooling of the results by doing meta-analysis.

The current development status of RBX in DPN is not clear. If any further clinical trials of PKC-β inhibitor are undertaken, we feel it is essential that it should be of at least 1 year duration with the use of clear methods of randomization, allocation concealment, and blinding and having good follow-up of subjects. Also results should be reported properly with all statistical values.

In conclusion, implications for practice: RBX had effects on DPN in some studies which the evidence is not enough for firm conclusion. Implications for research: further research with PKC inhibitors should only involve compounds with substantial biological or preclinical advantages over RBX. Any future trials should last at least 1 year, use rigorous methodology, and employ clinically relevant outcome measures.

No potential conflict of interest relevant to this article was reported.
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###### 

Study design characteristics

![](dmj-37-375-i001)

Casellini 1 and Casellini 2 are conference abstracts while Casellini is full text article.

NR, not reported; RBX, ruboxistaurin; PL, placebo; TPX, topiramate; FD, fixed dose; DPN, diabetic peripheral neuropathy; NTSS-6, neurological total symptom score (points); NIS (LL), neuropathy impairment score of lower limbs; VDT, vibration detection threshold; SNAP, sural neurological action potential (µv); SkBF, skin microvascular blood flow; QoL, quality of life; NIS, neurological impairment score (points); CGI, clinician global impression; NSS, neuropathy symptom score (points); TNS, total neurological score (points).

^a^Sixty-six were assigned to 32 mg/day & 71 to 64 mg/day group, ^b^TPX vs. PL and RBX vs. PL was separately compared, ^c^Fixed dose given in mg/day.

###### 

Baseline characteristics of patients included in studies

![](dmj-37-375-i002)

PL, placebo; RBX, ruboxistaurin; NTSS-6, neurological total symptom score (points); NR, not reported; VDT, vibration detection threshold; NIS, neurological impairment score (points); NIS (LL), neurological impairment score of lower limbs; NSS, neuropathy symptom score (points); DPN, diabetic peripheral neuropathy.

^a^Participants age is expressed in years (here mean±standard deviation \[SD\] is mentioned), except for Boyd (mean±standard error of mean \[SEM\]) and Casellini (mean±interquartile range \[IQR\]), ^b^Duration of diabetes is expressed in years (here mean±SD is mentioned), except for Boyd (mean±SEM), ^c^Duration of DPN is expressed in years (here mean±SD is mentioned), except for Boyd (mean±SEM).

###### 

Parameters assessed for diabetic peripheral neuropathy^a^

![](dmj-37-375-i003)

NR, not reported; SEM, standard error of mean; IQR, interquartile range.

^a^At dose of 32 mg/day, ^b^Difference between ruboxistaurin and placebo is mentioned, ^c^Values mentioned are difference between baseline and posttreatment, ^d^Refers to parameter used as a primary end point in that particular study, ^e^Values are expressed in area under the curve×10^3^ blood flow units measured at proximal calf.
